The Role of Cytoflavin as Adjuvant Therapy in Acute Stroke in Evolution: A Case Report at Dr. Chasbullah Abdul Majid Regional Hospital, Bekasi City

Tranggono Yudo Utomo, Daniel Jhosias Samosir, Agus Yudawijaya

Abstract


Ischemic stroke results from reduced cerebral blood flow due to vascular occlusion, while Acute Stroke in Evolution (ASE) is characterized by progressive neurological deterioration during the acute phase. Cytoflavin has been proposed as an adjuvant neuroprotective therapy because of its potential to support cellular metabolism and tolerance to hypoxia; however, clinical evidence regarding its role in ASE remains limited, particularly in patients with multiple vascular risk factors. To document serial changes in neurological deficit, assessed using the National Institutes of Health Stroke Scale (NIHSS), and the safety of Cytoflavin as an adjuvant therapy in a single case of ASE with multiple risk factors. This was a prospective single-case report of a 38-year-old man with lacunar ischemic stroke managed at Dr. Chasbullah Abdul Majid Regional Hospital, Bekasi City. Clinical progression was evaluated through serial neurological examinations, NIHSS assessments, and head computed tomography (CT). The patient presented with sudden right-sided weakness, dysarthria, and facial deviation. His vascular risk factors included uncontrolled diabetes mellitus, hypertension, obesity, dyslipidemia, and smoking. The initial NIHSS score was 5, and head CT demonstrated a left basal ganglia lacunar infarction. On day four, neurological deficits worsened, with right-sided motor strength decreasing to 2/5 and the NIHSS score increasing to 12, consistent with ASE. Intravenous Cytoflavin 500 mg in 100 mL 0.9% NaCl three times daily was administered for 10 days. Neurological improvement began on day six. By day ten, motor strength improved to 5−, the patient was able to ambulate with mild hemiparesis, and the NIHSS score decreased to 4. The neurological improvement was temporally associated with the administration of Cytoflavin and comprehensive supportive management. No significant safety concerns were observed during treatment. In this single uncontrolled case of ASE, administration of Cytoflavin as an adjuvant therapy was temporally associated with improvement in neurological deficits, reflected by a reduction in NIHSS from 12 to 4 over 10 days. However, no causal inference can be drawn from a single uncontrolled case. These findings highlight the need for randomized controlled trials to determine the efficacy and safety of Cytoflavin as an adjuvant neuroprotective therapy in patients with ASE.

 

Keywords: Cytoflavin, Stroke Iskemik, NIHSS, Infark Lacunar

Full Text:

PDF

References


Bailey, R. R., Serra, M. C., & McGrath, R. P. (2020). Obesity and diabetes are jointly associated with functional disability in stroke survivors. Disability and Health Journal, 13(3), 100914. https://doi.org/10.1016/j.dhjo.2020.100914

Duan, Z.-W., Li, Z.-N., Zhai, Y.-J., Liu, T.-F., Zhang, C.-C., Hu, T., Wei, X.-E., Rong, L.-Q., & Liu, H.-Y. (2025a). Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. World Journal of Diabetes, 16(3), 94491. https://doi.org/10.4239/wjd.v16.i3.94491

Duan, Z.-W., Li, Z.-N., Zhai, Y.-J., Liu, T.-F., Zhang, C.-C., Hu, T., Wei, X.-E., Rong, L.-Q., & Liu, H.-Y. (2025b). Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. World Journal of Diabetes, 16(3), 94491.https://doi.org/10.4239/wjd.v16.i3.94491

Ekker, M. S., Verhoeven, J. I., Schellekens, M. M. I., Boot, E. M., Van Alebeek, M. E., Brouwers, P. J. A. M., Arntz, R. M., Van Dijk, G. W., Gons, R. A. R., Van Uden, I. W. M., Den Heijer, T., De Kort, P. L. M., De Laat, K. F., Van Norden, A. G. W., Vermeer, S. E., Van Zagten, M. S. G., Van Oostenbrugge, R. J., Wermer, M. J. H., Nederkoorn, P. J., … De Leeuw, F.-E. (2023). Risk Factors and Causes of Ischemic Stroke in 1322 Young Adults. Stroke, 54(2), 439–447.

https://doi.org/10.1161/STROKEAHA.122.040524

Ermine, C. M., Bivard, A., Parsons, M. W., & Baron, J.-C. (2021). The ischemic penumbra: From concept to reality. International Journal of Stroke, 16(5), 497–509. https://doi.org/10.1177/1747493020975229

Feske, S. K. (2021). Ischemic stroke. The American Journal of Medicine, 134(12), 1457–1464. https://doi.org/10.1016/j.amjmed.2021.07.027

Furie, K. (2020). Epidemiology and Primary Prevention of Stroke. Continuum, 26(2), 260–267. https://doi.org/10.1212/CON.0000000000000831

Herpich, F., & Rincon, F. (2020). Management of acute ischemic stroke. Critical Care Medicine, 48(11), 1654–1663. https://doi.org/10.1097/CCM.0000000000004597

Kharitonova, T., Shvarts, Y. G., Verbovoy, A. F., Orlova, N. S., Puzyreva, V. P., & Strokov, I. A. (2022). Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (C. BMJ Open Diabetes Research & Care, 10(3).

Kurnia.ekaptiningrum. (2023). Mengulik Tantangan dan Peluang Manajemen Stroke Iskemik Akut. In Universitas Gadjah Mada. https://ugm.ac.id/id/berita/mengulik-tantangan-dan-peluang-manajemen-stroke-iskemik-akut/

Palacio, S., McClure, L. A., Benavente, O. R., Bazan, C., Pergola, P., & Hart, R. G. (2014). Lacunar Strokes in Patients With Diabetes Mellitus: Risk Factors, Infarct Location, and Prognosis: The Secondary Prevention of Small Subcortical Strokes Study. Stroke, 45(9), 2689–2694. https://doi.org/10.1161/STROKEAHA.114.005018

Pan, S., Yu, B., Chen, Y., Gao, Y., Xie, W., Jin, Y., Zhou, G., Lou, J., Zhang, R., Chen, C., Weng, Y., & Chen, G. (2025). Electrolyte Levels in Poor Prognosis and Early Neurological Deterioration in Patients With Acute Ischemic Stroke. The Journal of Clinical Hypertension, 27(4), e70037. https://doi.org/10.1111/jch.70037

Powers, W. J. (2020). Acute Ischemic Stroke. New England Journal of Medicine, 383(3), 252–260. https://doi.org/10.1056/NEJMcp1917030

Qawasmeh, M. Al, Aldabbour, B., Momani, A., Obiedat, D., Alhayek, K., Kofahi, R., Yassin, A., & El-Salem, K. (2020). Epidemiology, Risk Factors, and Predictors of Disability in a Cohort of Jordanian Patients with the First Ischemic Stroke. Stroke Research and Treatment, 2020, 1–9. https://doi.org/10.1155/2020/1920583

Rahnemayan, S., Vakilipour, P., Ala, A., Mehdizadehfar, E., Gharabaghi, M. A., Roumiani, P. H., Shali, E. G., & Vahdati, S. S. (2025). A four-year assessment of demographic information, clinical presentations, risk factors and outcomes in lacunar stroke patients. BMC Neurology, 25(1), 248. https://doi.org/10.1186/s12883-025-04264-8

Timur, I. R., Tunjung, I. W., Iing, I., & Setiarini, R. (2025). Relationship Between Family History of Stroke, Hypertension and Smoking History with The Incidence of Ischemic Stroke in Stroke Patients. Jurnal Biologi Tropis, 25(1), 471–483. https://doi.org/10.29303/jbt.v25i1.8493

Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., Commodore-Mensah, Y., Elkind, M. S. V, Evenson, K. R., Eze-Nliam, C., Fugar, S., Generoso, G., Heard, D. G., Hiremath, S., Ho, J. E., … Subcommittee, on behalf of the A. H. A. C. on E. and P. S. C. and S. S. (2023). Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation, 147(8). https://doi.org/10.1161/CIR.0000000000001123

Wu, Z.-P., Wei, W., Liu, S., Hu, M.-D., Zhao, H., Li, X.-F., & Chen, X. (2025). The effect of hypertension, obesity, and type 2 diabetes on lacunar stroke: A network Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases, 35(6), 103974. https://doi.org/10.1016/j.numecd.2025.103974

Yi, Y., Liu, Z., Wang, M., Sun, M., Jiang, X., Ma, C., Xie, F., & Ma, X. (2021). Penumbra in Acute Ischemic Stroke. Current Neurovascular Research, 18(5), 572–585. https://doi.org/10.2174/1567202619666211231094046




DOI: http://dx.doi.org/10.30829/contagion.v8i3.28706

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 Tranggono Yudo Utomo, Daniel Jhosias Samosir, Agus Yudawijaya

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Contagion: Scientific Periodical Journal of Public Health and Coastal Health by Program Studi Ilmu Kesehatan Masyarakat is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.